Pharmaceutical formulation affects titanocene transferrin interactions.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Dalton Transactions

• Publication date

  2011-09-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c1dt10805kPMID 21847473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis, characterization and biological studies of alkenyl‐substituted titanocene(IV) carboxylate complexes

  2010cited by this paper
• Mechanisms of cytotoxicity of anticancer titanocenes.

  2010cited by this paper
• Modern cytotoxic titanium(IV) complexes; Insights on the enigmatic involvement of hydrolysis

  2009cited by this paper
• Inequivalent contribution of the five tryptophan residues in the C-lobe of human serum transferrin to the fluorescence increase when iron is released.

  2009cited by this paper
• Reconsideration of serum Ti(IV) transport: albumin and transferrin trafficking of Ti(IV) and its complexes.

  2008cited by this paper
• HPLC-ICPMS and stable isotope-labeled approaches to assess quantitatively Ti(IV) uptake by transferrin in human blood serum.

  2008cited by this paper
• Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives.

  2007cited by this paper
• Synthesis, Ti(IV) intake by apotransferrin and cytotoxic properties of functionalized titanocene dichlorides

  2007cited by this paper
• A new series of titanocene dichloride derivatives bearing cyclic alkylammonium groups: Assessment of their cytotoxic properties

  2007cited by this paper
• Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo

  2007cited by this paper
• Calorimetric, spectroscopic, and model studies provide insight into the transport of Ti(IV) by human serum transferrin.

  2007cited by this paper
• Determination of the titanium content of human transferrin by inductively-coupled plasma-atomic-emission spectroscopy

  2006cited by this paper
• Cellular toxicities of new titanocene dichloride derivatives containing pendant cyclic alkylammonium groups

  2006cited by this paper
• Ti(IV) binds to human serum transferrin more tightly than does Fe(III).

  2005cited by this paper
• Water-soluble titanocene complexes with sulfur-containing aminoacids: synthesis, spectroscopic, electrochemical and Ti(IV)–transferrin interaction studies

  2005cited by this paper
• Antitumor titanium compounds and related metallocenes.

  2004cited by this paper
• Synthesis, Characterization, and Assessment of Cytotoxic Properties of a Series of Titanocene Dichloride Derivatives

  2004cited by this paper
• Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride

  2004cited by this paper
• Antitumor titanium compounds.

  2003cited by this paper
• Titanium complexes in cancer treatment.

  2002cited by this paper
• Spectral and metal-binding properties of three single-point tryptophan mutants of the human transferrin N-lobe.

  2001cited by this paper
• Antitumour metallocenes: structure-activity studies and interactions with biomolecules.

  2000cited by this paper
• Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer

  2000cited by this paper
• Competitive binding of the anticancer drug titanocene dichloride to N,N′-ethylenebis(o-hydroxyphenylglycine) and adenosine triphosphate: a model for TiIV uptake and release by transferrin

  2000cited by this paper
• Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride.

  2000cited by this paper
• Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.

  1999cited by this paper
• Formation of titanium(IV) transferrin by reaction of human serum apotransferrin with titanium complexes

  1999cited by this paper
• Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.

  1998cited by this paper
• The First Specific TiIV -Protein Complex: Potential Relevance to Anticancer Activity of Titanocenes.

  1998cited by this paper
• Anti-proliferative activity and mechanism of action of titanocene dichloride.

  1998cited by this paper
• Phase II trial of titanocene dichloride in advanced renal-cell carcinoma

  1998cited by this paper
• Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.

  1998cited by this paper
• Binding and Transport of Nonferrous Metals by Serum Transferrin

  1998cited by this paper
• In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer.

  1994cited by this paper
• Mono- and dinuclear titanium(III)/titanium(IV) complexes with 1,4,7-trimethyl-1,4,7-triazacyclononane (L). Crystal structures of a compositionally disordered green and a blue form of [LTiCl3]. Structures of [LTi(O)(NCS)2], [LTi(OCH3)Br2](ClO4), and [L2Ti2(O)2F2(.mu.-F)](PF6)

  1992cited by this paper
• Potential radiopharmaceuticals labeled with titanium-45.

  1991cited by this paper
• Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects.

  1990cited by this paper
• Heterogeneity of the human transferrin receptor and use of anti‐transferrin receptor antibodies to detect tumours in vivo

  1987cited by this paper
• Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma.

  1987cited by this paper
• Calculation of equilibrium constants from multiwavelength spectroscopic data-IV Model-free least-squares refinement by use of evolving factor analysis.

  1986cited by this paper
• Tumor inhibition by titanocene complexes: activity against sarcoma 180.

  1986cited by this paper
• Hydrolysis chemistry of the metallocene dichlorides M(.eta.5-C5H5)2Cl2, M = titanium, vanadium, or zirconium. Aqueous kinetics, equilibria, and mechanistic implications for a new class of antitumor agents

  1985cited by this paper
• Calculation of equilibrium constants from multiwavelength spectroscopic data--II: SPECFIT: two user-friendly programs in basic and standard FORTRAN 77.

  1985cited by this paper
• Calculation of equilibrium constants from multiwavelength spectroscopic data-III Model-free analysis of spectrophotometric and ESR titrations.

  1985cited by this paper
• Hydrolysis chemistry of the metallocene dichlorides M(η5-C5H5)2Cl2, M=Ti, V, Zr. Aqueous kinetics, equilibria, and mechanistic implications for a new class of antitumor agents

  1985cited by this paper
• Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice.

  1985cited by this paper
• Calculation of equilibrium constants from multiwavelength spectroscopic data-I Mathematical considerations.

  1985cited by this paper
• Thermodynamic binding constants for gallium transferrin.

  1983cited by this paper
• Tumor inhibition by titanocene dichloride: First clues to the mechanism of action

  1980cited by this paper
• Transferrin and transferrin receptors in carcinoma of the breast.

  1980cited by this paper
• The distribution of iron between the metal-binding sites of transferrin human serum.

  1980cited by this paper
• Titanocene dichloride--the first metallocene with cancerostatic activity.

  1979cited by this paper
• Human serotransferrin: structure and function

  1977cited by this paper
• The synergistic binding of anions and Fe3+ by transferrin. Implications for the interlocking sites hypothesis.

  1975cited by this paper

• Novel Bimetallic Oxido-bridged Phenolato HafniumIV Complex with Enhanced Anti-tumor Activity and Aqueous stability

  2023cites this paper
• Superstoichiometric Binding of the Anticancer Agent Titanocene Dichloride by Human Serum Transferrin and the Accompanying Lobe Closure.

  2022cites this paper
• Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs

  2020cites this paper
• DNA Cleavage by a De Novo Designed Protein-Titanium Complex.

  2020cites this paper
• Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action.

  2019cites this paper
• Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies

  2019cites this paper
• Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer

  2018cites this paper
• A ubiquitous metal, difficult to track: towards an understanding of the regulation of titanium(iv) in humans.

  2017cites this paper
• Titanium Dioxide Nanoparticles Evoke Proinflammatory Response during Murine Norovirus Infection Despite Having Minimal Effects on Virus Replication.

  2016cites this paper
• Unusual Synergism of Transferrin and Citrate in the Regulation of Ti(IV) Speciation, Transport, and Toxicity.

  2016cites this paper
• Inhibition of hydroxyapatite formation in the presence of titanocene–aminoacid complexes: an experimental and computational study

  2015cites this paper
• Organometallic Titanocene–Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties

  2014cites this paper
• Biodistribution of Metals and Metallodrugs

  2013cites this paper
• Bioinorganic chemistry of titanium.

  2012cites this paper